- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00920595
Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors
August 14, 2012 updated by: Cephalon
An Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP-1 and PARP-2 Inhibitor) as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors
An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 as single-agent therapy and as combination therapy with temozolomide in patients with advanced solid tumors.
Study Overview
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nantes, France, 44805
- Cephalon Investigational Site
-
-
-
-
-
Newcastle upon Tyne, United Kingdom, NE7 7DN
- Cephalon Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient has a histologically or cytologically confirmed malignant advanced solid tumor considered unresponsive or poorly responsive to accepted treatment modalities.
- The patient has adequate hematologic assessments and adequate renal and hepatic functions as specified in the study protocol.
- The patient has measurable or nonmeasurable disease documented with an appropriate method of evaluation according to disease characteristics.
- The patient has had no chemotherapy for at least 3 weeks and has resolution of prior sequelae. If the patient has had prior curative radiation or prior treatment with nitrosoureas, a minimum of 4 weeks and 6 weeks, respectively, must have elapsed before treatment with CEP-9722.
- The patient has had no immunotherapy, including monoclonal antibody therapy, for at least 4 weeks and no hormonotherapy for at least 1 week, with the exception of patients with prostate cancer, who may continue hormonal therapy.
- The patient has a European Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- The patient has a life expectancy of 12 weeks or more.
- Agreement by women of childbearing potential (not surgically sterile or 2 years postmenopausal) to use a medically accepted method of contraception and continue the use of this method for the duration of the study and for 90 days after participation in the study. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
- Agreement by men not surgically sterile or who are capable of producing offspring to practice abstinence or use a barrier method of birth control, and continue use of this method for the duration of the study and for 6 months after participation in the study.
Exclusion Criteria:
- The patient has a primary brain tumor whose disease requires a systematic premedication with anticonvulsive agents.
- The patient has baseline cardiac abnormalities outside of the specified study parameters.
- The patient has clinically symptomatic recurrent/progressive brain metastases within 4 weeks (stable sequelae are acceptable).
- The patient has previous hypersensitivity reactions to 1 of the components of CEP-9722, temozolomide, or dacarbazine.
- The patient is a pregnant or breast-feeding woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
- The patient is participating in another interventional clinical study at the time of enrollment, has participated in another interventional clinical study within 4 weeks prior to enrollment, or the patient has previously been already enrolled in this study.
- The patient has an active gastroduodenal ulcer, uncontrolled high blood pressure, uncontrolled diabetes mellitus, or uncontrolled angina pectoris; has had a recent myocardial infarction; has had a cerebrovascular event within 6 months prior to study entry; or has pre-existing coagulopathy.
- The patient has a concomitant uncontrolled infection or severe systemic disease.
- The patient has a known nephropathy or hepatopathy.
- The patient is receiving concurrent treatment with an antineoplastic agent other than temozolomide.
- The patient has had previous treatment with another PARP inhibitor.
- The patient is unable to swallow capsules.
- The patient has taken any medications which are contraindicated as specified in the study protocol.
- The patient has any serious or uncontrolled nonmalignant medical disorder or psychiatric disorder.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
CEP-9722 alone and in combination therapy with temozolomide.
|
Starting dose of CEP-9722 is 150 mg/day (total dose).
The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5).
Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determination of Maximum Tolerated Dose (MTD) upon Dose Limiting Toxicities (DLT) data
Time Frame: Up to 42 days
|
Up to 42 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameters
Time Frame: Days 1 and 5 of Cycle 1 and on Day 5 of Cycle 2
|
Days 1 and 5 of Cycle 1 and on Day 5 of Cycle 2
|
Pharmacodynamics assay
Time Frame: Days 1, 5, and 8 of both Cycle 1 and Cycle 2
|
Days 1, 5, and 8 of both Cycle 1 and Cycle 2
|
Efficacy - will be assessed by the proportion of patients who achieve tumor response during the study
Time Frame: A 14-day cycle and at least one 28-day cycle
|
A 14-day cycle and at least one 28-day cycle
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sponsor's Medical Expert, MD, Cephalon France
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
October 1, 2011
Study Completion (Actual)
October 1, 2011
Study Registration Dates
First Submitted
June 11, 2009
First Submitted That Met QC Criteria
June 12, 2009
First Posted (Estimate)
June 15, 2009
Study Record Updates
Last Update Posted (Estimate)
August 16, 2012
Last Update Submitted That Met QC Criteria
August 14, 2012
Last Verified
August 1, 2012
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on CEP-9722
-
Teva Branded Pharmaceutical Products R&D, Inc.Terminated
-
CephalonCompletedSolid Tumors or Mantle Cell LymphomaBelgium, France
-
CephalonCompleted
-
CephalonCompletedPsoriasisUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
CephalonH. Lundbeck A/S; The Parkinson Study GroupTerminatedParkinson DiseaseUnited States, Canada, Puerto Rico
-
University of Michigan Rogel Cancer CenterRecruitingPancreatic Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Carcinoma | Adenosquamous Carcinoma | Gastrointestinal Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Carcinoma | Neuroendocrine Prostate CarcinomaUnited States
-
New Approaches to Neuroblastoma Therapy ConsortiumNational Cancer Institute (NCI)CompletedNeuroblastomaUnited States, Canada
-
Edwards LifesciencesCompletedCoronary Artery Disease | Heart Failure | Aortic Valve Stenosis | Aortic Valve Insufficiency | Aortic Valve DisorderCanada, United States, Austria, Germany, Spain, United Kingdom